TopStocks.com - Premium Stock Alerts

    Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

    June 16, 2026 · TopStocks

    Share
    • Intellectual property update confirms pelareorep’s unique manufacturing process and scalability

    • Previously filed method-of-use patent application expected to provide protection into 2046

    • Additional patent filings planned in 2026 to further expand the pelareorep intellectual property estate

    SAN DIEGO, June 16, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a new patent broadly protecting the Company's proprietary manufacturing process for pelareorep.

    The newly issued patent covers key aspects of the methods used to manufacture pelareorep and is expected to provide intellectual property protection into 2044. The patent is designed to protect the Company’s ability to consistently produce pelareorep at commercial scale and represents a significant addition to Oncolytics’ growing intellectual property portfolio.

    The Company also announced that a previously filed method-of-use patent application directed at pelareorep’s use as an immunotherapy remains under review and, if issued, is expected to provide protection into the year 2046. In addition, Oncolytics plans to file further patent applications this year that are designed to expand and strengthen the pelareorep intellectual property estate across additional therapeutic applications, treatment settings, and combination approaches.

    “Building a strong intellectual property estate around pelareorep is an important part of our strategy as we advance the program toward potential registration and commercialization,” said Jared Kelly, Chief Executive Officer of Oncolytics. “This newly issued patent strengthens our protection around the manufacturing of pelareorep and supports our ability to produce the product at commercial scale. Combined with our previously filed method-of-use patent application and additional planned filings, we continue to build a durable patent portfolio designed to support the long-term value of pelareorep. Checking this box represents another important milestone as we execute on our strategy and move pelareorep into its next phase of development.”

    The Company’s intellectual property strategy is focused on protecting pelareorep through a combination of manufacturing, method-of-use, formulation, and combination therapy patents designed to support the continued development and commercialization of pelareorep across multiple oncology indications.

    About Oncolytics Biotech Inc.

    Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically “cold” tumors to “hot” through the activation of innate and adaptive immune responses.

    The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep has received Fast Track designation from the FDA for colorectal and pancreatic cancer. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on LinkedIn and on X @oncolytics.

    Forward-Looking Statements

    This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include statements regarding beliefs as to the potential, registration, mechanism of action and benefits of pelareorep as a cancer therapeutic; the Company’s goals, strategies, and objectives; expectations around the design, milestones, anticipated timelines and expected outcomes for current and future studies, its belief in the clinical promise of pelareorep in anal, colorectal, pancreatic and other gastrointestinal cancers; the Company’s goals and expectations for its potential registrational development path for pelareorep in multiple gastrointestinal cancers; and plans for future disclosure of clinical trial results. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics’ public filings with securities regulators in the United States and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law.

    Company Contact:

    Jon Patton

    Director of IR & Communication

    jpatton@oncolytics.com

    Enjoyed this breakdown?

    Don't miss our next early stock alert.
    Join our SMS list and get real time picks sent straight to your phone the moment we release them.

    Fast, free, zero spam. Opt out anytime.

    By joining, you agree to receive recurring SMS alerts from TopStocks. Message and data rates may apply. Reply STOP to unsubscribe.

    MASTER LEGAL DISCLAIMER

    Last Updated: July 12, 2026

    Publisher: Relqo Media LLC (Wyoming, United States)

    Subject Company: Oncolytics Biotech Inc. (ONCY)

    IMPORTANT SUMMARY — PLEASE READ FIRST

    This website and any affiliated digital materials are published by Relqo Media LLC, a Wyoming marketing agency that has been compensated in cash by Oncolytics Biotech Inc. to produce and distribute promotional content regarding Oncolytics Biotech Inc. (NASDAQ: ONCY). This communication is a paid advertisement, not a research report, not investment advice, and not an independent publication. Relqo Media is not a broker-dealer, investment adviser, or securities analyst. Investing in small-cap or microcap securities is extremely speculative and may result in the total loss of your investment. We strongly urge all viewers to consult a licensed investment professional and perform their own due diligence.

    1. NATURE AND INTENT OF THIS COMMUNICATION

    Relqo Media LLC is a for-profit marketing agency engaged in paid promotions of public companies. The content we produce is strictly commercial and intended to create temporary public awareness, visibility, and short-term market activity around the featured company. This material is not impartial. All readers should interpret our content as a paid commercial advertisement and not as an editorial, research article, or independent commentary. We create advertisements, not analysis. These Communications are not intended to be factual evaluations of the company’s operations or investment merit.

    2. COMPENSATION FOR Oncolytics Biotech Inc. (ONCY)

    Relqo Media LLC has received cash compensation for the publication, distribution, and dissemination of investor awareness and promotional materials relating to Oncolytics Biotech Inc. (NASDAQ: ONCY).

    Relqo Media LLC has received forty thousand dollars ($40,000) for promotional services to be rendered during a five-day campaign commencing on July 13, 2026 and concluding on July 17, 2026. The compensation was paid directly by Oncolytics Biotech Inc., the issuer.

    Relqo Media LLC previously received fifty thousand dollars ($50,000) for promotional services rendered during a five-day campaign commencing on June 15, 2026 and concluding on June 20, 2026. The compensation was paid directly by Oncolytics Biotech Inc., the issuer.

    The aggregate cash compensation received by Relqo Media LLC in connection with these promotional and investor awareness campaigns relating to Oncolytics Biotech Inc. is ninety thousand dollars ($90,000).

    This compensation arrangement creates a direct, material, and unavoidable conflict of interest.

    As a result of the compensation described above, all materials, publications, communications, opinions, and content disseminated by Relqo Media LLC concerning Oncolytics Biotech Inc. must be considered paid promotional content and not independent, objective, or unbiased analysis.

    Relqo Media LLC is not a registered broker-dealer, investment adviser, or securities analyst, and is not acting in any such capacity. Nothing disseminated by Relqo Media LLC constitutes investment advice, an offer to sell, or a solicitation of an offer to buy any securities. Recipients should conduct their own independent due diligence and consult with licensed financial and legal professionals before making any investment decisions.

    Neither Relqo Media LLC nor Oncolytics Biotech Inc. makes any representation, warranty, or guarantee regarding the accuracy, completeness, or timeliness of the information disseminated, and each expressly disclaims any liability for losses that may arise from reliance on such promotional materials.

    Relqo Media LLC, its officers, members, affiliates, contractors, and related parties do not own any shares of Oncolytics Biotech Inc. (NASDAQ: ONCY) as of the date of publication of this disclaimer

    3. INTENDED AUDIENCE

    These Communications are directed solely to U.S.-based, self-directed investors who understand the risks of investing in microcap and Nasdaq-listed securities. The content is not intended for children, seniors, retirement accounts, or individuals with limited experience in securities trading. These Communications are not intended to guide investment for long-term portfolio management or financial planning purposes.

    4. NO ENDORSEMENT OR VERIFICATION OF COMPANY CLAIMS

    Relqo Media LLC does not, and has not, independently verified, investigated, audited, or substantiated any statements, representations, or claims made by the featured company, its officers, directors, employees, affiliates, agents, press releases, marketing materials, or any third-party sources.

    Any and all information regarding Oncolytics Biotech Inc. (NASDAQ: ONCY)—including but not limited to business descriptions, operational updates, clinical trial progress, scientific data, partnerships, revenue projections, market opportunity estimates, or strategic plans—should be assumed to be unverified, unaudited, incomplete, potentially inaccurate, and subject to change without notice.

    We make no warranties or representations as to the truthfulness, accuracy, reliability, or completeness of such information, and you should not interpret our publication of these statements as an endorsement or confirmation of their validity.

    You should not rely on any company-provided claims, projections, or forward-looking statements for the purpose of making an investment decision. All such statements may be speculative, overstated, selectively presented, or based on assumptions that may never materialize.

    If you choose to invest, you do so entirely at your own risk, and you should conduct thorough, independent due diligence—including reviewing SEC filings, consulting licensed investment professionals, and obtaining independent verification of any material facts—before making any investment decision.

    5. MARKET INFLUENCE AND TRADING PATTERN EXPECTATION

    Historically, promotional campaigns for microcap and small-cap securities—particularly those driven by paid advertising—often cause temporary, artificial, and unsustainable increases in share price and trading volume. These movements are typically fueled by short-term speculative interest, promotional circulation, algorithmic trading activity, and momentum-based retail buying rather than any change in the underlying business, operations, or financial condition of the company.

    You should assume and expect that:

    • ONCY’s share price may experience sharp, rapid, and potentially extreme increases during the period of active promotion;
    • Trading volume may spike dramatically due to speculative buying pressure, news catalysts amplified by promotional activity, and social media or online forum chatter;
    • Once buying interest subsides, selling begins, or the promotion ends—which may occur suddenly and without notice—the share price may decline precipitously, potentially returning to pre-promotion levels or lower, often within days or even hours; and
    • These price and volume movements are not reflective of intrinsic value and may have no correlation to the company’s actual fundamentals or long-term business prospects.

    Past market behavior shows that such promotional price spikes are frequently followed by steep losses, which can be rapid and irreversible. If you purchase shares during or shortly after a promotional period, you should be prepared for the high probability of losing a substantial portion, or all, of your investment.

    By engaging with our content, you acknowledge and agree that you fully understand the speculative, volatile, and high-risk nature of securities subject to promotional activity, and you will not hold Relqo Media LLC responsible for any losses resulting from such trading patterns.

    6. NO RELIANCE – INVESTOR RESPONSIBILITY

    The burden of research, verification, and risk assessment rests entirely with you, the reader. All content produced and distributed by Relqo Media LLC is promotional in nature and should not be the basis for any investment decision. We are not responsible for your interpretation or use of the information contained herein.

    You are solely responsible for:

    • Reviewing and analyzing all publicly available information, including but not limited to SEC filings, audited financial statements, and official company disclosures;
    • Consulting with a licensed, qualified investment professional, attorney, or tax adviser before making any investment decision;
    • Understanding and accepting the risks inherent in microcap and early-stage public companies, which may include extreme volatility, illiquidity, lack of financial transparency, insider selling, share dilution, regulatory challenges, and business failure.

    We make no warranties or representations as to the accuracy, completeness, timeliness, or reliability of any information presented. Any data, figures, or statements regarding the featured company’s business, market opportunity, future performance, or partnerships may be incomplete, outdated, or incorrect. You should assume that certain information is based on third-party sources we have not independently verified.

    By viewing our materials, you agree that:

    • You will not rely solely on our communications in making an investment decision;
    • You accept full responsibility for conducting independent due diligence; and
    • Relqo Media LLC and its affiliates will not be liable for any losses or damages arising from your reliance on our content.

    7. FORWARD-LOOKING STATEMENTS, ASSUMPTIONS, AND ACCURACY NOTICE

    Our materials may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as well as other predictive or aspirational language regarding future events, performance, or results. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “may,” “will,” “should,” “could,” “projects,” “estimates,” “potential,” and similar expressions are intended to identify such statements. These statements are inherently uncertain, based on current expectations, estimates, and assumptions that may prove to be incorrect, incomplete, or no longer applicable at the time you read them.

    Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to: changes in market conditions, regulatory decisions, the outcome of clinical trials, competitive pressures, the availability of financing, and broader economic or geopolitical developments.

    Additionally, some information presented in our content is derived from third-party sources, company press releases, or statements from officers, directors, or affiliates of the featured company. We do not independently verify or guarantee the accuracy, completeness, or timeliness of such information. Any claim, projection, or forward-looking statement should be considered purely speculative and potentially outdated..

    You should not place undue reliance on forward-looking statements or assume that they will prove to be accurate. Relqo Media LLC undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events, changes in circumstances, or the emergence of new information, except as required by law.

    8. INFORMATION SOURCING, BIAS, AND ACCURACY

    We use publicly available information including company websites, press releases, and promotional materials supplied by paying clients or related parties. We do not verify or validate this data.

    Assume all information presented by Relqo Media is:

    • Subjective,
    • Not independently verified,
    • Created to highlight potential upside and omit downsides,
    • Not suitable as the basis for any investment decision.

    9. OWNERSHIP AND TRADING CONFLICTS

    Relqo Media LLC, its contractors, members, and affiliates may hold or acquire shares in the companies we promote, including ONCY. We may buy or sell such shares without prior notice. These transactions may occur before, during, or after a promotional campaign and may affect market pricing. We are not obligated to update readers on our trading activity or affiliate holdings.

    10. MARKETING TOOLS, DATA COLLECTION, AND USER CONSENT

    We use a range of outreach and promotional tools, including:

    • Email and newsletter distributions,
    • SMS/MMS text campaigns,
    • Social media posts and influencers,
    • Google and native display ads,
    • Press releases, video marketing, and paid content distribution.

    By engaging with our content, you consent to receive ongoing marketing communications. You may unsubscribe, but your data may be retained for audit or compliance purposes. Please refer to our Privacy Policy for further details.

    11. ADVERTISING LAW COMPLIANCE

    Relqo Media LLC produces promotional content in accordance with the advertising disclosure standards set forth by the Federal Trade Commission (FTC) and the SEC’s interpretations of sponsored investment-related communications.

    We make good-faith efforts to disclose all:

    • Compensation arrangements,
    • Conflicts of interest,
    • Risks,
    • Limitations of our role, and
    • The promotional nature of this content.

    We do not provide investment recommendations under any regulatory framework including, but not limited to, SEC Regulation Analyst Certification, FINRA Rule 2210, or Regulation Best Interest.

    12. NON-U.S. USERS

    This material is intended solely for distribution within the United States. If you are accessing this site from outside the U.S., you are responsible for complying with your country’s laws. Relqo Media disclaims liability for access from non-U.S. jurisdictions where investor promotion, marketing, or solicitation of securities is restricted or prohibited.

    13. DISCLAIMER OF WARRANTIES AND LIMITATION OF LIABILITY

    All content is provided “as-is” and without warranties of any kind, either express or implied. Relqo Media LLC disclaims any and all liability for:

    • Investment losses,
    • Inaccuracies,
    • Technical delays,
    • User misunderstandings,
    • Omissions or errors in content.

    Total liability for any claim shall not exceed one hundred dollars ($100).

    14. LEGAL GOVERNANCE AND DISPUTE RESOLUTION

    All matters arising out of this disclaimer shall be governed by the laws of the State of Wyoming. You agree that any dispute shall be resolved exclusively through binding arbitration under the rules of the American Arbitration Association, to be held in Sheridan County, Wyoming. Class action claims and group arbitration are expressly prohibited.

    15. NON-SOLICITATION AND GEOGRAPHIC LIMITATIONS

    Nothing in our content constitutes a general solicitation or a personal securities recommendation. If you reside in a jurisdiction where such communications are unlawful, you must exit this site and discontinue engagement with our content.

    16. FINAL NOTICE – ACCEPTANCE OF TERMS

    We reserve the right to update this Disclaimer at any time without notice. Your continued use of our services or content constitutes acceptance of the most recent version.

    If you do not accept all terms of this disclaimer in full, you must:

    • Exit our websites,
    • Unsubscribe from our communications,
    • Discontinue viewing all Relqo Media promotional content.

    17. NO RELIANCE

    By viewing or engaging with this content, you agree that:

    • You will not rely on any statements made by Relqo Media for investment purposes,
    • You waive any claim that our content was a material factor in your investment decision,
    • You have read, understood, and accepted this disclaimer in full.

    © 2024 Relqo Media LLC. All Rights Reserved.

    Legal Contact: 📧 support@topstocks.com

    Mailing Address: 1309 Coffeen Ave Ste 1200, Sheridan, WY 82801

    Affiliate Disclosure: Relqo Media LLC owns and operates TopStocks.com and all affiliated digital properties.